A study by Jia in 2023 aimed to find out if ropivacaine inhibits the malignant behavior of lung cancer cells by regulating retinoblastoma-binding protein 4 and found that ropivacaine suppresses lung cancer cell malignancy by downregulating RB binding protein 4 expression, which may help clarify the mechanisms underlying the antitumor effects of ropivacaine [47]. This evidence concerns the gene RBBP4 and lung carcinoma.